Cempra Inc (CEMP)

7.45
0.35 4.93
NASDAQ : Health Care
Prev Close 7.10
Open 7.05
Day Low/High 7.05 / 7.60
52 Wk Low/High 6.50 / 24.25
Volume 143.79K
Avg Volume 842.60K
Exchange NASDAQ
Shares Outstanding 52.51M
Market Cap 122.35M
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Cempra, Inc. And Encourages Investors With Losses To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Cempra, Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Cempra, Inc.

Cempra Antibiotic Approval Still in Doubt Even With Positive FDA Panel Vote

Cempra Antibiotic Approval Still in Doubt Even With Positive FDA Panel Vote

By a slim 7-6 margin, experts convened by the FDA decided the benefits of solithromycin outweighed its potential safety problems in treating patients with community-acquired bacterial pneumonia.

Cempra (CEMP) Stock Downgraded at JPMorgan on FDA Pneumonia Drug Review

Cempra (CEMP) Stock Downgraded at JPMorgan on FDA Pneumonia Drug Review

JPMorgan analysts believe the safety concerns raised by the FDA after reviewing Cempra's (CEMP) Solithera drug could set 'a very high bar' for approval.

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Cempra, Inc. And Advises Investors With Losses To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Cempra, Inc. And Advises Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Cempra, Inc.

'Mad Money' Lightning Round: J.C. Penney Is 'A Lot Better,' Jim Cramer Says

'Mad Money' Lightning Round: J.C. Penney Is 'A Lot Better,' Jim Cramer Says

Jim Cramer says JCP is better, but 'just OK,' and investors should be careful with CEMP.

Jim Cramer's 'Mad Money' Recap: It's Chicago Versus Cleveland -- Stocks, That Is

Jim Cramer's 'Mad Money' Recap: It's Chicago Versus Cleveland -- Stocks, That Is

Jim Cramer says the market can have many winners.

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces An Investigation Of Cempra, Inc. And Encourages Investors With Losses To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces An Investigation Of Cempra, Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces that it is investigating claims against Cempra, Inc.

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into Cempra Inc. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into Cempra Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into Cempra Inc.

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

Here's a window into what institutional investors may be doing and how to profit from that.

Cempra Reports Third Quarter 2016 Financial Results And Provides Corporate Update

Cempra Reports Third Quarter 2016 Financial Results And Provides Corporate Update

Management to host webcast and conference call today at 5:00 p.m. EDT

Cempra To Report Third Quarter 2016 Financial Results

Cempra To Report Third Quarter 2016 Financial Results

—Management to host webcast and conference call on Thursday, October 27, 2016 at 5:00 p.m. EDT—

Cempra Is Ready to Run

Cempra Is Ready to Run

Given predictable upcoming catalysts and a large addressable market, this small-cap biotech is a buy.

These 5 Biotech Stocks Are Ready for a Volatility Break

These 5 Biotech Stocks Are Ready for a Volatility Break

The squeeze is on these stocks, and they are poised for volatile moves.

Cempra To Present Solithromycin At FDA Antimicrobial Drugs Advisory Committee Meeting On November 4, 2016

Cempra To Present Solithromycin At FDA Antimicrobial Drugs Advisory Committee Meeting On November 4, 2016

FDA currently reviewing NDAs for IV and oral solithromycin for community-acquired bacterial pneumonia, with PDUFA dates in late December

Cempra Announces European Medicines Agency Validates MAA For Solithromycin For Treatment Of CABP

Cempra Announces European Medicines Agency Validates MAA For Solithromycin For Treatment Of CABP

Formal review of solithromycin by EMA now underway

Perilous Reversal Watch: Cempra (CEMP)

Perilous Reversal Watch: Cempra (CEMP)

Trade-Ideas LLC identified Cempra (CEMP) as a "perilous reversal" (up big yesterday but down big today) candidate

Cempra (CEMP) Is Today's Strong On High Volume Stock

Cempra (CEMP) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Cempra (CEMP) as a strong on high relative volume candidate